# US 2012/0232098 A1 · Methods of predicting and treating adverse cardiac events

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232098 A1
- Document ID: US20120232098A1
- Status: Published application
- Kind: A1
- Application number: 13/476,394
- Filed: 2012-05-21
- Published: 2012-09-13
- Earliest claimed: 2008-03-05
- Inventors: Mohan Rajapurkar; Suhas Lele; Sudhir Shah
- Web page: https://patentgrep.com/patent/US20120232098A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/84: involving inorganic compounds or pH
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/325: Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- Y10S 435/97: Test strip or test slide
- Y10S 435/973: Simultaneous determination of more than one analyte
- Y10S 435/975: Kit
- Y10S 436/807: Apparatus included in process claim, e.g. physical support structures
- Y10S 436/808: Automated or kit
- Y10S 436/81: Tube, bottle, or dipstick
- Y10S 436/811: Test for named disease, body condition or organ function
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention provides methods for treatment of acute coronary syndrome and prediction of adverse cardiac events on the basis of elevations of catalytic iron in biological fluid of a human subject. An embodiment of the invention provides a method for early detection of acute coronary syndrome (ACS) in a human subject at the time of presentation of the chest pain. The method includes analyzing a test sample of the biological fluid for amount of catalytic iron and detecting acute coronary syndrome in the human subject.

## Claims

### Claim 1

A method of treating an adverse cardiac event in a human, comprising the step of administering an iron chelator to a human suspected of having an adverse cardiac event.

### Claim 2 (depends on 1)

The method of claim 1, further including the steps of:
a) measuring catalytic iron and at least one clinical indicia of the adverse cardiac event in a first biological fluid sample obtained from the human; and
b) administering an additional iron chelator to the subject if catalytic iron in the first biological fluid sample exceeds that of a control catalytic iron, or if at least one clinical indicia indicates the human is continuing to have the adverse cardiac event following measurement of the catalytic iron and the clinical indicia of the adverse cardiac event, thereby treating the adverse cardiac event in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the adverse cardiac event is at least one member selected from the group consisting of acute coronary syndrome, heart failure, reinfarction, stent thrombosis and blood vessel damage.

### Claim 4 (depends on 2)

The method of claim 2, wherein the clinical indicia of the adverse cardiac event is at least one member selected from the group consisting of chest pain, abnormal electrocardiogram and elevated troponin I levels.

### Claim 5 (depends on 2)

The method of claim 2, wherein the first biological fluid sample is at least one member selected from the group consisting of a blood sample, a serum sample and a plasma sample.

### Claim 6 (depends on 2)

The method of claim 2, wherein the first biological fluid sample is obtained from the human about 0-6 hours after the onset of a chest pain in the human.

### Claim 7 (depends on 2)

The method of claim 2, further including the step of obtaining a second biological fluid sample from the human about 24 hours after the first biological fluid sample is obtained.

### Claim 8 (depends on 7)

The method of claim 7, wherein the second biological fluid sample is at least one member selected from the group consisting of a blood sample, a serum sample and a plasma sample.

### Claim 9 (depends on 7)

The method of claim 7, further including the step of measuring catalytic iron in the second biological fluid sample, wherein an elevation in catalytic iron in the second biological fluid sample compared to catalytic iron in the first biological fluid sample indicates the human is continuing to have the adverse cardiac event.

### Claim 10 (depends on 9)

The method of claim 9, further including the step of administering the additional iron chelator to the human.

### Claim 11

A method of predicting an adverse cardiac event in a human suspected of having an adverse cardiac event, comprising the step of measuring catalytic iron in a first biological fluid sample obtained from the human suspected of having an adverse cardiac event, whereby an increase in catalytic iron in the first biological sample compared to catalytic iron in a control sample predicts that the human is having the adverse cardiac event.
